Cargando…

Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients

BACKGROUND: The mevalonate pathway synthetizes cholesterol, steroid hormones, and non-steriod isoprenoids necessary for cell survival. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway and the target for statin treatment. HMGCR expression i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gustbée, Emma, Tryggvadottir, Helga, Markkula, Andrea, Simonsson, Maria, Nodin, Björn, Jirström, Karin, Rose, Carsten, Ingvar, Christian, Borgquist, Signe, Jernström, Helena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479235/ https://www.ncbi.nlm.nih.gov/pubmed/26109908 http://dx.doi.org/10.1186/s12907-015-0008-2

Ejemplares similares

Interactions Between ABCB1 Genotype and Preoperative Statin Use Impact Clinical Outcomes Among Breast Cancer Patients
por: Tryggvadottir, Helga, et al.
Publicado: (2018)

HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome
por: Bengtsson, Erik, et al.
Publicado: (2014)

Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer
por: Borgquist, Signe, et al.
Publicado: (2008)

Coffee Is Associated With Lower Breast Tumor Insulin-Like Growth Factor Receptor 1 Levels in Normal-Weight Patients and Improved Prognosis Following Tamoxifen or Radiotherapy Treatment
por: Björner, Sofie, et al.
Publicado: (2018)

Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: Implications for prognosis in different treatment groups
por: Björner, Sofie, et al.
Publicado: (2016)

Excessive milk production during breast-feeding prior to breast cancer diagnosis is associated with increased risk for early events
por: Gustbée, Emma, et al.
Publicado: (2013)

Body Mass Index Influences the Prognostic Impact of Combined Nuclear Insulin Receptor and Estrogen Receptor Expression in Primary Breast Cancer
por: Björner, Sofie, et al.
Publicado: (2017)

Patient Characteristics Influence Activated Signal Transducer and Activator of Transcription 3 (STAT3) Levels in Primary Breast Cancer—Impact on Prognosis
por: Nilsson, Linn, et al.
Publicado: (2020)

Prognostic impact of tumor-specific insulin-like growth factor binding protein 7 (IGFBP7) levels in breast cancer: a prospective cohort study
por: Godina, Christopher, et al.
Publicado: (2021)

Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen
por: Brennan, Donal J, et al.
Publicado: (2011)

Re-evaluation of HER2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment
por: Sandén, Emma, et al.
Publicado: (2020)

CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients
por: Kimbung, Siker, et al.
Publicado: (2020)

The Prognostic Impact of Intratumoral Aryl Hydrocarbon Receptor in Primary Breast Cancer Depends on the Type of Endocrine Therapy: A Population-Based Cohort Study
por: Tryggvadottir, Helga, et al.
Publicado: (2021)

Interplay between Caveolin-1 and body and tumor size affects clinical outcomes in breast cancer
por: Godina, Christopher, et al.
Publicado: (2022)

IL6 genotype, tumour ER-status, and treatment predicted disease-free survival in a prospective breast cancer cohort
por: Markkula, Andrea, et al.
Publicado: (2014)

Increasing preoperative body size in breast cancer patients between 2002 and 2016: implications for prognosis
por: Wisse, Agatha, et al.
Publicado: (2018)

Predictive Modeling of HMG-CoA Reductase Inhibitory Activity and Design of New HMG-CoA Reductase Inhibitors
por: Samizo, Shigeyoshi, et al.
Publicado: (2023)

CYP1A2 – a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients
por: Simonsson, Maria, et al.
Publicado: (2016)

Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort
por: Persson, Mia, et al.
Publicado: (2016)

Pre- and postoperative alcohol consumption in breast cancer patients: impact on early events
por: Simonsson, Maria, et al.
Publicado: (2014)

Pleiotropic effects of the HMG-CoA reductase inhibitors
por: Mihos, Christos G, et al.
Publicado: (2011)

Prognostic Impact of Menopausal Hormone Therapy in Breast Cancer Differs According to Tumor Characteristics and Treatment
por: Godina, Christopher, et al.
Publicado: (2020)

Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients
por: Markkula, Andrea, et al.
Publicado: (2014)

Caveolin-1 genotypes as predictor for locoregional recurrence and contralateral disease in breast cancer
por: Godina, Christopher, et al.
Publicado: (2023)

The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation
por: Gelosa, Paolo, et al.
Publicado: (2007)

Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo
por: Noël, Martin, et al.
Publicado: (2004)

Structural and functional characterization of HMG-COA reductase from Artemisia annua
por: Kiran, Usha, et al.
Publicado: (2010)

Transcription of the three HMG-CoA reductase genes of Mucor circinelloides
por: Nagy, Gábor, et al.
Publicado: (2014)

Functional Implications of HMG-CoA Reductase Inhibition on Glucose Metabolism
por: Han, Ki Hoon
Publicado: (2018)

Chronic Onset Form of Anti-HMG-CoA Reductase Myopathy
por: Lorenzo-Villalba, Noel, et al.
Publicado: (2021)

Eupatilin Alleviates Hyperlipidemia in Mice by Inhibiting HMG-CoA Reductase
por: Kim, Kyung-Joo, et al.
Publicado: (2023)

Are Point Mutations in HMG-CoA Reductases (Hmg1 and Hmg2) a Step towards Azole Resistance in Aspergillus fumigatus?
por: Gonzalez-Jimenez, Irene, et al.
Publicado: (2021)

Pre- and Postoperative Circulating IGF-I, IGFBP-3, and IGFBP-7 Levels in Relation to Endocrine Treatment and Breast Cancer Recurrence: A Nested Case-Control Study
por: Rosendahl, Ann H., et al.
Publicado: (2021)

The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases
por: Friesen, Jon A, et al.
Publicado: (2004)

Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase
por: Würtz, Peter, et al.
Publicado: (2016)

The prenyltransferase UBIAD1 is the target of geranylgeraniol in degradation of HMG CoA reductase
por: Schumacher, Marc M, et al.
Publicado: (2015)

Impact of combining vitamin C with radiation therapy in human breast cancer: does it matter?
por: Khazaei, Somayeh, et al.
Publicado: (2022)

Degradation of HMG-CoA reductase-induced membranes in the fission yeast, Schizosaccharomyces pombe
Publicado: (1995)

Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer
por: Solanki, Abhishek A, et al.
Publicado: (2011)

Lepidopteran HMG-CoA reductase is a potential selective target for pest control
por: Li, Yuan-mei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rud4dbomk2sqn114gqfgrmsvsm